This resource list has been compiled by the Cystinosis Research Foundation for cystinosis patients and their families as a quick reference to assist you with your questions concerning insurance, and the process necessary to obtain medications and prescriptions. This information is intended for general education and should not be construed as advising on diagnosis or treatment of this or any other medical condition.

AAKP Scholarship Program for Cystinosis Patients

The American Association of Kidney Patients (AAKP) just finalized their Cystinosis Scholarship Program. This is a great program for people with cystinosis, ages 5+, to utilize and eliminate possible financial hurdles to participate in curricular or extracurricular programs.
To apply, click this link!  


Cystagon® capsules contain cysteamine bitartrate, a cystine depleting agent that lowers the cystine content of cells in patients with cystinosis. CVS ProCare is the sole distributor for Cystagon®. 
Contact CVS ProCare:
Hours of Operation (EST): Monday – Friday: 8 a.m. – 8 p.m. Saturday: 8 a.m. – 1 p.m. 
CVS ProCare provides the following services: 
Counseling on ordering Cystagon®
Ordering other medications
Insurance inquiries
Trained pharmacist assistance available 24 hours  


Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States.  New dosage form in tear-open packets provides a convenient option for people living with cystinosis. Read full announcement.  View frequently asked questions.  
Patients should talk with their doctor to determine if PROCYSBI (cysteamine bitartrate) delayed-release capsules is right for them. More information on this medicine is available at, including details on Horizon Pharma’s TrancendRare™, a patient-support program created with input from people with nephropathic cystinosis and their caregivers. For the general nephropathic cystinosis community, TranscendRare offers educational information as well as tools to help manage the disease. For eligible people on PROCYSBI, TranscendRare offers access and reimbursement support to help you stay on track with your treatment. Patients must make an appointment with their doctor to determine if PROCYSBI is right for them. Please visit the Horizon Pharma website for more information. Horizon Pharma purchased Raptor Pharmaceuticals in 2016.  


CYSTADROPS® (cysteamine ophthalmic solution) 0.37% is an eye drop solution that was approved in the US in August 2020 and is the first and only FDA-approved cysteamine drop formulation with four times a day dosing. Clinical trials of CYSTADROPS® demonstrated a significant reduction in cystine crystal deposits in all layers of the cornea in people with cystinosis. CYSTADROPS® requires a prescription and is available from Anovo Specialty Pharmacy (866-925-6212).  


Leadiant Biosciences, Inc. is pleased to announce that CYSTARAN® (cysteamine ophthalmic solution) 0.44% eye drops are back in stock at AllianceRx Walgreens Prime. 
With the reintroduction of CYSTARAN, Leadiant is pleased to announce the CYSTARAN Voucher Program. Through this program, cystinosis patients in the U.S. may be eligible for a FREE 1-month supply of CYSTARAN (4 bottles)*. Information about the Free Voucher Program along with the Enrollment Form can be downloaded below or is also available at  To enroll in the CYSTARAN Voucher Program or order CYSTARAN, please call AllianceRx Walgreens Prime at 1-877-534-9627 or see Free Voucher Offer below. 
If you have any questions about CYSTARAN, please do not hesitate to reach out to me for more information or visit 
Thank you,
Lesli King
Leadiant Letter to the Community 
Cystaran Free Voucher Offer      


Appointments with Dr. William Gahl 
Joy C. Bryant, RN, BSN, CCRC
Research Nurse Specialist
301-443-8690, 102-10460 (page)
National Human Genome Research Institute National Institutes of Health
9000 Rockville Pike
Building 10/Room 3-2551
Bethesda, Maryland 20892


The Cystinosis Research Foundation is dedicated to finding better treatments to improve the quality of life for those with cystinosis and to ultimately find a cure for this devastating disease. The Cystinosis Research Foundation issues grants for bench and clinical research studies bi-annually in order to accelerate research progress and ensure that cystinosis research is on-going and focused on novel treatments and a cure. The Cystinosis Research Foundation is also dedicated to educating the public and the medical community about cystinosis to ensure early diagnosis and proper treatment. 


NORD’s vision and guiding principles on which our advocacy initiatives are based:

  • A national awareness and recognition of the challenges faced by people living with rare diseases and the associated costs to society.
  • A nation where people with rare diseases can secure access to diagnostics and therapies that extend and improve their lives.
  • A social, political and financial culture of innovation that supports both the basic and translational research necessary to create diagnostic tests and therapies for all rare disorders.
  • A regulatory environment that encourages development and timely approval of safe and effective diagnostics and treatments for patients with rare diseases.



New Resource for Teens

Tips for Teens Living with Cystinosis and Kidney Disease   
Now Available in Spanish Versions

This booklet was developed for tweens and teens who have cystinosis and learn they now have kidney disease and will need dialysis or a transplant. The booklet provides a brief overview of coping with kidney disease, being part of their health care team, the importance of diet, taking medication, and treatment methods. It also touches on feelings related to having another chronic illness, family and friends, and being a teen. The development of this booklet included input from the cystinosis community,  kids currently on dialysis, parents, adults who had kidney disease as children, and nephrologists.